Swiss Military Consumer Goods
SWISSMLTRY.BO News Today: Stay Updated with the Latest Swiss Military Consumer Goods News in Real Time
Find SWISSMLTRY.BO news now at Meyka AI. Stay informed with the latest Swiss Military Consumer Goods stocks updates, including price news, market analysis, and expert insights.
0657.HK G-Vision International up 9.38% pre-market 27 Feb 2026: renewed buying interest
Pre-market look at 0657.HK stock on 27 Feb 2026 — price, volume, valuation and Meyka AI forecast for investors
UBS Stock Today: February 26 — Credit Suisse Platform Shutdown Starts March
UBS Credit Suisse integration enters its final phase as UBS starts shutting Credit Suisse platforms from end-March. See the migration timeline, impact on Swiss clients, cost synergies, and UBS stock’s
AYV.SI stock volume spike to S$0.19 on 26 Feb 2026: watch follow-through
AYV.SI stock closed S$0.19 on 26 Feb 2026 after a volume spike; analysis, Meyka AI grade and forecast included
760,141 shares: SRIND.BO S.R. Industries (BSE) 26 Feb 2026: liquidity shift
SRIND.BO stock saw a volume spike to 760,141 on BSE 26 Feb 2026; Meyka AI flags liquidity change and sets targets
RRVAS (RSE Archive LLC) $25.10 PNK 26 Feb 2026: 1.46x volume trade signal
RRVAS stock trades at $25.10 on PNK with 1.46x volume on 26 Feb 2026, analysis and Meyka AI forecast
123,145 volume: BKM Industries (BKMINDST.BO BSE) 26 Feb 2026 liquidity alert
BKMINDST.BO stock saw a volume spike to 123,145 on 26 Feb 2026; price INR 1.81 at close, watch liquidity and technical setup
Rosmah Mansor Recusal Bid Rejected; Appeal Moved to March 3 — February 26
Rosmah Mansor recusal bid rejected by Malaysia’s Federal Court; appeal moved to March 3 due to medical leave. What it means for Singapore investors watching governance risk.
GUI.DE stock down 14.81% intraday on 26 Feb 2026: Weak US demand drags price lower
GUI.DE stock plunges to €18.40 intraday on 26 Feb 2026 after outlook cut; Meyka AI forecast and grade included
IDIA.SW Stock Today: FY2025 Revenue Doubles; Loss Narrows — February 26
Idorsia stock steadied near CHF 3.75 as FY2025 revenue doubled to CHF 221m and losses narrowed. Quviviq sales hit CHF 134m. 2026 guidance targets CHF 200m Quviviq and an operating loss of CHF -160m.